TREM-1 Gene Polymorphisms
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Triggering receptor expressed on myeloid cells-1 (TREM-1) is a cell surface receptor expressed on neutrophils and monocytes. TREM-1 acts to amplify inflammation and serves as a critical mediator of inflammatory response in the context of sepsis. Blocking of TREM-1 can protect against sepsis in mice. This study was designed to investigate whether TREM-1 genomic variations were associated with the prognosis of sepsis. We sequenced 30 sepsis patients with TREM-1 gene of four exons by PCR sequencing. When analyzing the results of sequencing, we found two gene polymorphisms located in exon-2 and exon-4, respectively. Compare with the NCBI dbSNP and Hapmap database, one polymorphisms located in exon-2 is non-synonymous variation rs2234237（Ser25Thr）, the other one located in exon-4 is synonymous variation rs2234246. Two common polymorphisms (rs2234237,rs2234246) within the TREM-1 gene were detected in 80 patients with severe sepsis and in 80 healthy control subjects. This study was explored that whether or not polymorphisms detected within the TREM-1 gene may play a major role in the predisposition to prognosis of sepsis in a Chinese Han cohort.
| Condition |
|---|
|
Sepsis |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Association Between TREM-1 Gene Polymorphisms and Prognosis in Sepsis Patient |
- Patients Outcome [ Time Frame: 28 days ] [ Designated as safety issue: No ]The survival time of patients more than 28days is defined as survival. The survival time of patients less than 28days is defined as death
| Enrollment: | 160 |
| Study Start Date: | May 2010 |
| Study Completion Date: | October 2011 |
| Primary Completion Date: | October 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
sepsis
SIRS plus inflammation
|
|
Control
normal person under medical examination
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
All subjects were selected from among inpatients who were hospitalized between September 2009 and October 2011 in the Respiratory ICU, Surgical ICU, and Emergency ICU, Chinese People's Liberation Army (CPLA) General Hospital.
Inclusion Criteria:
- Sepsis met the criteria recommended by 1991 ACCP/SCCM Joint Meeting and by the diagnostic criteria developed at the 2001 International Sepsis Definition Conference.
Exclusion Criteria:
- (1) younger than 18 years of age; (2) acquired immunodeficiency syndrome; (3) reduced polymorphonuclear granulocyte counts (< 500 μL-1); (4) died within 24h after admission into the ICU, or refused to participate in the study, or declined treatment during the period of observation.
Contacts and Locations| China, Beijing | |
| Chinese PLA General Hospital | |
| Beijing, Beijing, China, 100853 | |
| Study Director: | Lixin Xie, MD | Respiratory Disease Department of chinese PLA General Hospital |
More Information
No publications provided by Chinese PLA General Hospital
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT01490424 History of Changes |
| Other Study ID Numbers: | 20111013-009（2）, 2009BAI86B03 |
| Study First Received: | December 12, 2011 |
| Last Updated: | December 12, 2011 |
| Health Authority: | China: Ethics Committee |
Keywords provided by Chinese PLA General Hospital:
|
TREM-1; SNPs; prognosis control（normal person） |
Additional relevant MeSH terms:
|
Sepsis Toxemia Infection |
Systemic Inflammatory Response Syndrome Inflammation Pathologic Processes |
ClinicalTrials.gov processed this record on May 23, 2013